Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy comparative rates of overall mortality and sudden cardiac death after treatment

Circulation: Cardiovascular Interventions

Volumn 3, Issue 2, 2010, Pages 97-104

  Leonardi, Robert A ^a   Kransdorf, Evan P ^b   Simel, David L ^b   Wang, Andrew ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Hypertrophic cardiomyopathy; Meta analysis; Myectomy; Septal ablation

Indexed keywords

ALCOHOL SEPTAL ABLATION; ARTICLE; CARDIOVASCULAR PROCEDURES; CLINICAL TRIAL; HEART SURGERY; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; INTERMETHOD COMPARISON; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; SEPTAL REDUCTION THERAPY; SUDDEN DEATH; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT OUTCOME;

ABLATION TECHNIQUES; ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHY, HYPERTROPHIC; CAUSE OF DEATH; DEATH, SUDDEN, CARDIAC; ETHANOL; FEMALE; HEART SEPTUM; HUMANS; REGRESSION ANALYSIS;

EID: 77953655040     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.109.916676     Document Type: Article

References (43)

1. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH III, Spirito P, ten Cate FJ, Wigle ED. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42:1687-1713. (Pubitemid 37383745)
2. Schulte HD, Borisov K, Gams E, Gramsch-Zabel H, Lösse B, Schwartzkopff B. Management of symptomatic hypertrophic obstructive cardiomyopathy-long-term results after surgical therapy. Thorac Cardiovasc Surg. 1999;47:213-218.
3. University of Idaho College of Agriculture. SAS workshop GENMOD. Available at: http://www.uiweb.uidaho.edu/ag/statprog/index.html. Accessed August 21, 2009.
4. Heric B, Lytle BW, Miller DP, Rosenkranz ER, Lever HM, Cosgrove DM. Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results. J Thorac Cardiovasc Surg. 1995;110:195-206;
5. discussion 206-208.
6. Krajcer Z, Leachman RD, Cooley DA, Coronado R. Septal myotomymyomectomy versus mitral valve replacement in hypertrophic cardiomyopathy. Ten-year follow-up in 185 patients. Circulation. 1989;80:157-164.
7. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:470-476.
8. Robbins RC, Stinson EB. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 1996;111:586-594.
9. Schonbeck MH, Brunner-La Rocca HP, Vogt PR, Lachat ML, Jenni R, Hess OM, Turina MI. Long-term follow-up in hypertrophic obstructive cardiomyopathy after septal myectomy. Ann Thorac Surg. 1998;65:1207-1214.
10. Schulte HD, Bircks WH, Loesse B, Godehardt EA, Schwartzkopff B. Prognosis of patients with hypertrophic obstructive cardiomyopathy after transaortic myectomy. Late results up to twenty-five years. J Thorac Cardiovasc Surg. 1993;106:709-717.
11. Smedira NG, Lytle BW, Lever HM, Rajeswaran J, Krishnaswamy G, Kaple RK, Dolney DO, Blackstone EH. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg. 2008;85:127-133.
12. Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, Siu S, Ralph-Edwards A, Rakowski H. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation. 2005;111:2033-2041.
13. Airoldi F, Di Mario C, Catanoso A, Dharmadhikari A, Tzifos V, Anzuini A, Carlino M, Briguori C, Montorfano M, Vaghetti M, Tolaro S, Colombo A. Progressive decrease of outflow gradient and septum thickness after percutaneous alcoholization of the interventricular septum in hypertrophic obstructive cardiomyopathy. Ital Heart J. 2000;1:200-206.
14. Boekstegers P, Steinbigler P, Molnar A, Schwaiblmair M, Becker A, Knez A, Haberl R, Steinbeck G. Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001;38:846-853.
15. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H. One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response. Clin Res Cardiol. 2007;96:864-873.
16. Fernandes VL, Nielsen C, Nagueh SF, Herrin AE, Slifka C, Franklin J, Spencer WH III. Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: the Baylor and Medical University of South Carolina experience 1996 to 2007. J Am Coll Cardiol Cardiovasc Interv. 2008;1:561-570.
17. Firoozi S, Elliott PM, Sharma S, Murday A, Brecker SJ, Hamid MS, Sachdev B, Thaman R, McKenna WJ. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J. 2002;23:1617-1624.
18. Guo H, Wang P, Xing Y, Peng F, Jiang J, Yang B, You B, Qiu Y, Lee JD. Delayed electrocardiographic changes after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. J Electrocardiol. 2007;40:356 e351-e356.
19. Kazmierczak J, Kornacewicz-Jach Z, Kisly M, Gil R, Wojtarowicz A. Electrocardiographic changes after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Heart. 1998;80:257-262. (Pubitemid 28440344)
20. Kim JJ, Lee CW, Park SW, Hong MK, Lim HY, Song JK, Jin YS, Park SJ. Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy. Am J Cardiol. 1999;83:1220-1223.
21. Kuhn H, Lawrenz T, Lieder F, Leuner C, Strunk-Mueller C, Obergassel L, Bartelsmeier M, Stellbrink C. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience. Clin Res Cardiol. 2008;97:234-243.
22. Monakier D, Woo A, Puri T, Schwartz L, Ross J, Jamorski M, Yang H, Liu Z, Vannan M, Wigle ED, Rakowski H. Usefulness of myocardial contrast echocardiographic quantification of risk area for predicting postprocedural complications in patients undergoing septal ethanol ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2004;94:1515-1522.
23. Mutlak D, Gruberg L, Reisner S, Markiewicz W. Non-surgical myocardial reduction in hypertrophic obstructive cardiomyopathy. Isr Med Assoc J. 2002;4:86-90.
24. Oomman A, Ramachandran P, Subramanyan K, Kalarickal MS, Osman MN. Percutaneous transluminal septal myocardial ablation in drug-resistant hypertrophic obstructive cardiomyopathy: 18-month follow-up results. J Invasive Cardiol. 2001;13:526-530.
25. Osterne EC, Seixas TN, Paulo Filho W, Osterne EM, Gomes OM. Percutaneous transluminal septal alcoholization for the treatment of refractory hypertrophic obstructive cardiomyopathy: initial experience in the Federal District. Arq Bras Cardiol. 2003;80:359-378.
26. Qin JX, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, Bauer F, Greenberg NL, Agler DA, Drinko JK, Martin M, Tuzcu EM, Smedira NG, Lytle B, Thomas JD. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol. 2001;38:1994-2000.
27. Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, Hodge DO, Schaff HV, Holmes DR Jr. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008;118:131-139.
28. Streit S, Walpoth N, Windecker S, Meier B, Hess O. Is alcohol ablation of the septum associated with recurrent tachyarrhythmias? Swiss Med Wkly. 2007;137:660-668.
29. Tsuchikane E, Takeda Y, Kobayashi T, Yachiku K, Nasu K, Kobayashi Y, Matsumoto H, Awata N. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Circ J. 2003;67:763-767.
30. van der Lee C, Scholzel B, ten Berg JM, Geleijnse ML, Idzerda HH, van Domburg RT, Vletter WB, Serruys PW, ten Cate FJ. Usefulness of clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation. Am J Cardiol. 2008;101:1315-1320.
31. Veselka J, Duchonova R, Palenickova J, Zemanek D, Tiserova M, Linhartova K, Cervinka P. Impact of ethanol dosing on the long-term outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a single-center prospective, and randomized study. Circ J. 2006;70:1550-1552.
32. Borenstein M H L, Higgins J P T, Rothstein HR. Introduction to Meta-Analysis. West Sussex, UK: John Wiley and Sons; 2009:286-289.
33. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, Danielson GK, Quinones MA, Tajik AJ, Spencer WH. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001;38:1701-1706. (Pubitemid 33065457)
34. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. J Am Med Assoc. 1999;281:650-655.
35. Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA III, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P. Implantable cardioverterdefibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. J Am Med Assoc. 2007;298:405-412. (Pubitemid 47124061)
36. McLeod CJ, Ommen SR, Ackerman MJ, Weivoda PL, Shen WK, Dearani JA, Schaff HV, Tajik AJ, Gersh BJ. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2007;28:2583-2588.
37. Olivotto I, Ommen SR, Maron MS, Cecchi F, Maron BJ. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? J Am Coll Cardiol. 2007;50:831-834.
38. Candell-Riera J, Romero-Farina G, Galve E, Armadans L, Palet J, Castell-Conesa J. [Hypertrophic cardiomyopathy in adult patients. Clinical course and prognostic factors in 119 patients]. Med Clin (Barc). 2004;123:1-4.
39. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 2001;357:420-424.
40. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna WJ. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36:2212-2218.
41. Gueffet JP, Langlard JM, Burban M, Campion L, Bouhour JB. [Hypertrophic cardiomyopathy. Long-term clinical development in a regional cohort of 243 patients]. Arch Mal Coeur Vaiss. 2001;94:967-974.
42. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation. 1982;65:1388-1394.
43. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342:1778-1785.